Beike Biotechnology Opens World’s Largest Stem Cell Storage and Processing Facility
TAIZHOU,
one of the world’s leading biotechnology companies focusing on adult stem cell
therapies, and the
20,000 square-meter Stem Cell Regenerative Medicine Industrial Project of
National Bio-Industry Base (NBPD) houses
regenerative medicine technology center and its largest international stem
cell bank.
The Stem Cell Regenerative Medicine Industrial Facility gives Beike the
capacity to store and process 1 million copies of stem cells, making it the
largest and most sophisticated stem cell processing center of its kind in the
world. The visionary leadership of the Jiangsu Government and Beike set the
stage for this advancement when the partnership broke ground on the project
one year ago. The NBPD facility is part of multi-stage project that consists
of industry partnerships designed to provide a central research zone for
on this biotechnology incubation center include those from Fudan University,
Huazhong Science and Technology University, Nanjing University Medical School,
People’s Hospital.
“Stem cells are the crown jewel of medical research,” said Dr.
the center’s newly appointed VP for Medical, Scientific and Regulatory Affairs.
“We are honored China Medical City has chosen Beike as a partner to support
the world — not just in
Western countries — are engaged in the same work we are here in
City. We believe our work will serve as a model for them as we conduct this
important research designed to bring life-changing stem cell therapies to
patients.”
Dr. Song described the mission of the new center as aggressive development
of new, patented stem cell therapies along with the development of processes
and protocols that follow stringent implementation of international quality
benchmarks. He noted the center will have three main goals: adult stem cell
collection and storage, establishment of processes and protocols based on
international standards such as the American Association of Blood Banks (AABB),
the Foundation for the Accreditation of Cellular Therapy (FACT) standards and
ISO9001 certifications, and to patent and bring stem cell therapies to
clinical practice.
Dr. Shengqin Ye, CEO of Jiangsu Beike Biotech, said Beike’s recruitment of
the world-renowned cyropreservation scientist, Dr.
center’s Chief Scientific Officer is evidence of Beike’s commitment to quality
and safety. Dr. Ye said, “We are very pleased to have Dr. Song leading the
charge to establish rigorous quality system and stem cell industrialization
specifications. Dr. Song’s wide breadth of expertise and experience in
United States
conducts clinical trials.”
In addition to his quality management and banking/tissue efforts, Dr.
Song’s work with Beike includes oversight and coordination of the company’s
R&D and publications. Prior to joining Beike, Dr. Song was Scientific
Director of Xytex Research Inc., and Clinical Associate Professor in the
Department of Surgery and Institute of Molecular Medicine and Genetics, at the
surgery programs for the U.S.
He earned his M.D. at Xuzhou Medical College,
biophysics at the Medical Research Council,
is extensively published in the fields of vitrification and tissue engineering,
and is currently a member of the Editorial Board of Cryobiology.
The expansion of the Jiangsu Stem Cell Bank allows Beike to take an
integrated approach to the development of stem cell therapies. The facility
allows Beike’s scientists and physicians to produce the highest quality stem
cell therapies available in the world by providing processing, storage, and
clinical application development within an amalgamated and efficient framework.
(CMC), noted, “The grand opening of the largest stem cell management center in
the world; the Jiangsu Beike Biotech Stem Cell Bank here in the CMC,
solidifies the CMC’s position as a world center for biotechnology and
regenerative medicine. Supremacy in all aspects of stem cell management and
research is the foundation for our successful biotechnology development
strategy.”
About Beike Biotechnology Company Limited
Beike Biotechnology (http://www.beikebiotech.com ) is
biotechnology company focusing on adult stem cell therapies. Beike’s
scientists have been focused on the development and commercialization of adult
stem cell therapies since 1999. The company currently produces a full line of
stem cell products from umbilical cord, cord blood, and bone marrow stem cells.
Beike’s stem cell therapies are administered by physicians at many leading
hospitals throughout
Beike’s unique processing technologies prepare the cells for use in
treating a variety of serious medical conditions including ataxia, brain
injury, cerebral palsy, diabetic foot disease, lower limb ischemia, multiple
sclerosis, muscular dystrophy, spinal cord injury and optic nerve pathologies.
About China Medical City
Located on a 25-square kilometer site in the heart of Taizhou City in
Government in 2005 and has active support from the local government. It
represents
materials industry by concentrating all medical services and support in one
central location. The city of Taizhou is fast becoming
biotech location, with over 35% annual growth since 2004.
home to the largest concentration of
revenue generated over the past five years.
For more information, please contact:
Shenzhen Beike Biotechnology Company, Ltd.
T. Gutmann
Shenzhen Hi-Tech Industrial Park
Tel: +86-755-8630-9200
Email: info@beikebiotech.com
Web: http://www.beikebiotech.com
SOURCE Beike Biotechnology Company Limited